FindTrial
Sign In

Identification of Biomarkers for Early Detection of Pancreatic Cancer

Michigan Center for Pancreatic Cancer Molecular Diagnosis: The Serum Protein Microarray Project

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00897494
Enrollment
75
Registered
2009-05-12
Start date
2005-02-28
Completion date
2011-04-30
Last updated
2016-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer

Keywords

stage I pancreatic cancer, stage II pancreatic cancer, stage III pancreatic cancer, stage IV pancreatic cancer

Brief summary

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is examining blood samples from patients with cancer to identify biomarkers that may help in the early detection of pancreatic cancer.

Detailed description

OBJECTIVES: * Identify specific proteins of interest to evaluate for their potential role as markers for pancreatic cancer. * Analyze serum proteins directly by mass spectrometry to identify new biomarkers of pancreatic cancer that can be used for early diagnosis. OUTLINE: Blood from patients is collected prior to treatment. Plasma proteins are analyzed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF/MS) and/or electrospray mass spectrometry (ESI/MS). PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.

Interventions

GENETICprotein expression analysis

Venous blood collection

OTHERlaboratory biomarker analysis

Venous blood collection

OTHERmass spectrometry

Venous blood collection

OTHERsurface-enhanced laser desorption/ionization-time of flight mass spectrometry

Venous blood collection

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
Barbara Ann Karmanos Cancer Institute
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 120 Years
Healthy volunteers
No

Inclusion criteria

DISEASE CHARACTERISTICS: * Diagnosis of pancreatic cancer * Newly diagnosed disease * Planning to undergo surgery or other treatment for pancreatic cancer at Karmanos Cancer Institute or its affiliates PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Design outcomes

Primary

MeasureTime frame
Identification of specific proteins of interest to evaluate for their potential role as markers for pancreatic cancerUpon collection when patient agrees to provide a one time venous blood collection
Analysis of serum proteins directly by mass spectrometry to identify new biomarkers of pancreatic cancer that can be used for early diagnosisAfter separation from the plasma

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026